CN119930578A - 经取代1-氧代-异吲哚啉-5-羧酰胺化合物，其组合物，及以此治疗的方法 - Google Patents

经取代1-氧代-异吲哚啉-5-羧酰胺化合物，其组合物，及以此治疗的方法 Download PDF

Info

Publication number
CN119930578A
CN119930578A CN202510008872.0A CN202510008872A CN119930578A CN 119930578 A CN119930578 A CN 119930578A CN 202510008872 A CN202510008872 A CN 202510008872A CN 119930578 A CN119930578 A CN 119930578A
Authority
CN
China
Prior art keywords
compound
carboxamide
substituted
dioxopiperidin
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202510008872.0A
Other languages
English (en)
Chinese (zh)
Inventor
F·巴库利
K·诺斯柯特
M·D·科雷亚
J·汉森
L·A·勒布朗
C-C·鲁
G·鲁
M·A·纳吉
S·彭
S·佩林-宁科维奇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of CN119930578A publication Critical patent/CN119930578A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202510008872.0A 2019-05-31 2020-05-29 经取代1-氧代-异吲哚啉-5-羧酰胺化合物，其组合物，及以此治疗的方法 Pending CN119930578A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962855619P 2019-05-31 2019-05-31
US62/855,619 2019-05-31
PCT/US2020/035043 WO2020243379A1 (en) 2019-05-31 2020-05-29 Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith
CN202080040212.6A CN114269729B (zh) 2019-05-31 2020-05-29 经取代1-氧代-异吲哚啉-5-羧酰胺化合物，其组合物，及以此治疗的方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202080040212.6A Division CN114269729B (zh) 2019-05-31 2020-05-29 经取代1-氧代-异吲哚啉-5-羧酰胺化合物，其组合物，及以此治疗的方法

Publications (1)

Publication Number Publication Date
CN119930578A true CN119930578A (zh) 2025-05-06

Family

ID=73551319

Family Applications (4)

Application Number Title Priority Date Filing Date
CN202510008872.0A Pending CN119930578A (zh) 2019-05-31 2020-05-29 经取代1-氧代-异吲哚啉-5-羧酰胺化合物，其组合物，及以此治疗的方法
CN202080040212.6A Active CN114269729B (zh) 2019-05-31 2020-05-29 经取代1-氧代-异吲哚啉-5-羧酰胺化合物，其组合物，及以此治疗的方法
CN202410679319.5A Pending CN118724867A (zh) 2019-05-31 2020-05-29 经取代1-氧代-异吲哚啉-5-羧酰胺化合物，其组合物，及以此治疗的方法
CN202210612012.4A Active CN114957212B (zh) 2019-05-31 2020-05-29 经取代1-氧代-异吲哚啉-5-羧酰胺化合物，其组合物，及以此治疗的方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN202080040212.6A Active CN114269729B (zh) 2019-05-31 2020-05-29 经取代1-氧代-异吲哚啉-5-羧酰胺化合物，其组合物，及以此治疗的方法
CN202410679319.5A Pending CN118724867A (zh) 2019-05-31 2020-05-29 经取代1-氧代-异吲哚啉-5-羧酰胺化合物，其组合物，及以此治疗的方法
CN202210612012.4A Active CN114957212B (zh) 2019-05-31 2020-05-29 经取代1-氧代-异吲哚啉-5-羧酰胺化合物，其组合物，及以此治疗的方法

Country Status (19)

Country Link
US (2) US11306101B2 (https=)
EP (1) EP3976595A4 (https=)
JP (2) JP7496838B2 (https=)
KR (2) KR20250078628A (https=)
CN (4) CN119930578A (https=)
AR (1) AR119057A1 (https=)
AU (1) AU2020282748A1 (https=)
BR (1) BR112021022758A2 (https=)
CA (1) CA3136753A1 (https=)
CL (1) CL2021003134A1 (https=)
CO (1) CO2021015624A2 (https=)
IL (1) IL288278B2 (https=)
MX (1) MX2021014350A (https=)
MY (1) MY208545A (https=)
PE (1) PE20220569A1 (https=)
SG (1) SG11202112872YA (https=)
TW (2) TW202523657A (https=)
WO (1) WO2020243379A1 (https=)
ZA (1) ZA202109003B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020243379A1 (en) 2019-05-31 2020-12-03 Celgene Corporation Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith
IL302038A (en) * 2020-10-14 2023-06-01 C4 Therapeutics Inc Tricyclic ligands for degradation of ikzf2 or ikzf4
CN112679421A (zh) * 2021-01-04 2021-04-20 都创(上海)医药科技股份有限公司 一种(r)-3-氯吡啶基-2-三氟乙胺盐酸盐的合成方法
JP2024504932A (ja) 2021-01-13 2024-02-02 モンテ ローザ セラピューティクス， インコーポレイテッド イソインドリノン化合物
CN118019534A (zh) * 2021-05-06 2024-05-10 细胞基因公司 使用n-((r)-1-(3-氯吡啶-2-基)-2,2,2-三氟乙基)-2-((s)-2,6-二氧代哌啶-3-基)-1-氧代异吲哚啉-5-甲酰胺的治疗方法
US20240294500A1 (en) * 2021-06-08 2024-09-05 Hangzhou Glubio Pharmaceutical Co., Ltd. Isoindolinone compounds, and uses thereof
CN115504963A (zh) * 2021-06-22 2022-12-23 苏州开拓药业股份有限公司 一种c-Myc蛋白降解剂
EP4452415B1 (en) 2021-12-22 2026-02-25 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
CA3253296A1 (en) 2022-03-17 2023-09-21 Gilead Sciences, Inc. Zinc Finger Degradation Agents of the Ikaros Family and Their Uses
WO2023244815A1 (en) * 2022-06-16 2023-12-21 Monte Rosa Therapeutics, Inc. Molecular glue degraders and methods of using the same
WO2023244818A1 (en) * 2022-06-16 2023-12-21 Monte Rosa Therapeutics, Inc. Molecular glue degraders and methods of using the same
US20260055077A1 (en) * 2022-08-01 2026-02-26 Suzhou Kintor Pharmaceuticals, Inc. Protein degradation agent
WO2024120441A1 (zh) * 2022-12-07 2024-06-13 杭州格博生物医药有限公司 氧异吲哚-5-甲酰胺类化合物或其盐、溶剂合物的结晶形式或无定形形式
WO2024120438A1 (zh) * 2022-12-07 2024-06-13 杭州格博生物医药有限公司 一种固体分散体、其制备方法和应用
PL249026B1 (pl) * 2022-12-09 2026-02-23 Univ Mikolaja Kopernika W Toruniu Pochodna azetydyno-2,4-dionu, sposób jej otrzymywania i zastosowanie

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030045552A1 (en) * 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
US7091353B2 (en) * 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
KR20080042158A (ko) * 2005-08-31 2008-05-14 셀진 코포레이션 이소인돌-이미드 화합물과 이를 포함하는 조성물 및 이를이용한 방법
MX2009001989A (es) 2006-08-30 2009-03-09 Celgene Corp Compuestos de isoindolina 5-substituidos.
US8877780B2 (en) * 2006-08-30 2014-11-04 Celgene Corporation 5-substituted isoindoline compounds
ZA200901078B (en) * 2006-08-30 2010-06-30 Celgene Corp 5-substituted isoindoline compounds
US9499514B2 (en) * 2014-07-11 2016-11-22 Celgene Corporation Antiproliferative compounds and methods of use thereof
WO2017007612A1 (en) 2015-07-07 2017-01-12 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
WO2017024318A1 (en) * 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
WO2017024317A2 (en) * 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
WO2020243379A1 (en) 2019-05-31 2020-12-03 Celgene Corporation Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith

Also Published As

Publication number Publication date
JP2024123001A (ja) 2024-09-10
JP2022534979A (ja) 2022-08-04
CA3136753A1 (en) 2020-12-03
IL288278B1 (en) 2025-05-01
CO2021015624A2 (es) 2022-02-28
MY208545A (en) 2025-05-14
AU2020282748A1 (en) 2021-12-09
TWI851729B (zh) 2024-08-11
KR102913106B1 (ko) 2026-01-19
US20220213115A1 (en) 2022-07-07
SG11202112872YA (en) 2021-12-30
EP3976595A4 (en) 2023-01-04
TW202523657A (zh) 2025-06-16
CN114957212B (zh) 2024-05-24
MX2021014350A (es) 2022-02-21
CN114269729A (zh) 2022-04-01
BR112021022758A2 (pt) 2022-03-22
CN114269729B (zh) 2025-01-17
IL288278A (en) 2022-01-01
CN114957212A (zh) 2022-08-30
CL2021003134A1 (es) 2022-07-01
US20200377512A1 (en) 2020-12-03
ZA202109003B (en) 2025-01-29
KR20220016167A (ko) 2022-02-08
PE20220569A1 (es) 2022-04-20
JP7496838B2 (ja) 2024-06-07
TW202110819A (zh) 2021-03-16
US11306101B2 (en) 2022-04-19
CN118724867A (zh) 2024-10-01
IL288278B2 (en) 2025-09-01
KR20250078628A (ko) 2025-06-02
EP3976595A1 (en) 2022-04-06
US12486281B2 (en) 2025-12-02
WO2020243379A1 (en) 2020-12-03
AR119057A1 (es) 2021-11-17

Similar Documents

Publication Publication Date Title
CN114269729B (zh) 经取代1-氧代-异吲哚啉-5-羧酰胺化合物，其组合物，及以此治疗的方法
TWI814815B (zh) 經取代4-胺基異吲哚啉-1,3-二酮化合物、其組成物、及以此治療之方法
US20260098028A1 (en) Compounds and Their Use for Treatment of Hemoglobinopathies
EA050422B1 (ru) Замещенные 1-оксоизоиндолин-5-карбоксамидные соединения, содержащие их композиции и способы лечения с их помощью
JP7852160B2 (ja) 異常ヘモグロビン症の治療のための化合物およびその使用
EA046753B1 (ru) Замещенные 1-оксоизоиндолин-5-карбоксамидные соединения, содержащие их композиции и способы лечения с их помощью
US20250368620A1 (en) ARNT Degrading Compounds and Uses Thereof
TW202606669A (zh) Ａｒｎｔ降解化合物及其用途
CN119585267A (zh) 作为irak3的配体定向降解剂的取代的吡唑基-吡啶基化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination